Herceptin (trastuzumab) is one of these targeted medicines for breast cancer. It works against a protein called HER2 (also sometimes referred to as HER2/neu), which is short for human epidermal ...

Answer: Herceptin is a drug, an agent whose chemical name is 'trastuzumab.' It's a monoclonal antibody that interferes with the function of an important protein in some breast cancers: the HER2 ...

The new findings come from a study of more than 3,200 women with early breast cancer who were HER2 positive. Herceptin, an antibody therapy, targets the HER2 protein, which plays a role in cell ...

According to the FDA decision, announced yesterday, Herceptin may now be used in combination with other cancer drugs to treat HER2 positive breast cancer after surgery — either lumpectomy ...

Therapies that specifically target HER2 include Herceptin (trastuzumab), Perjeta (pertuzumab), and T-DM1 (trastuzumab emtansine) which is sold under the brand name Kadcycla. Treatment of early ...

The targeted therapy Herceptin helps women with HER2+ type of breast cancer independent of whether patients have extra copies of chromosome 17, home to the HER2 gene which produces the HER2 ...

The interim results from the international HERA (HERceptin Adjuvant) study provide new hope in the fight against HER2-positive breast cancer, a more aggressive form of the disease affecting ...

Adding Afinitor to Herceptin, the main treatment for HER2-positive metastatic breast cancer, helps some women with disease that has been resistant to previous Herceptin-based therapies ...

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)-- Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced the U.S. Food and Drug Administration (FDA) has approved ...

Eight years after its approval, Herceptin emerges as the best weapon against HER2-positive breast cancer. There are certain emotional moments that we all remember. The birth of a child. The death of a ...

Too many copies of the HER2 gene or its overexpression appeared to cause an especially aggressive form of the disease. By the late ’90s, a drug called Herceptin that targeted the HER2 receptor, sped ...

Herceptin is already indicated for the treatment of HER2-expressing metastatic breast cancer as a single agent in patients who have received one or more chemotherapy regimens; or in combination ...